Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.33 |
| ▸ | WNT3A | P56704 | 1/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 4/20 | 0.32 |
| ▸ | RAB9A | P51151 | 4/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | F2 | P00734 | 3/20 | 0.31 |
| ▸ | F10 | P00742 | 3/20 | 0.31 |
| ▸ | FURIN | P09958 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.30 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.30 |
| ▸ | FEN1 | P39748 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL760980 | 0.84 | AKR1C3 (0.48) | CTNNB1WNT3ANPC1RAB9AALDH1A1 | |
| SCHEMBL756187 | 0.81 | LMNA (0.35) | CTNNB1WNT3AKEAP1FAAHF2 | |
| SCHEMBL756184 | 0.81 | LMNA (0.35) | CTNNB1WNT3AKEAP1FAAHF2 | |
| SCHEMBL1973353 | 0.81 | HDAC8 (0.35) | HDAC8NPC1F2F10FURIN | |
| SCHEMBL762297 | 0.80 | GRIA2 (0.45) | KEAP1NPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL757861 | 0.78 | KDM4E (0.39) | HDAC8CTNNB1WNT3ANPC1RAB9A | |
| SCHEMBL760930 | 0.73 | TDP1 (0.41) | ALDH1A1SMN1; SMN2PKMKDM4EPOLB | |
| SCHEMBL760979 | 0.73 | KEAP1 (0.48) | KEAP1NPC1RAB9AFAAHKDM4E | |
| SCHEMBL5479492 | 0.71 | GRIA2 (0.38) | HDAC8 | |
| SCHEMBL756185 | 0.69 | KEAP1 (0.44) | HDAC8CTNNB1WNT3AKEAP1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569285-B2 | Dihydrobenzoxathiazepine compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2013-10-29 | — | — | US | disclosed |
| EP-2431360-B1 | Derivatives of dihydrobenzoxathiazepine, method of preparing same and pharmaceutical compositions containing them as well as their uses as modulators of AMPA receptors | SERVIER LAB (FR) | 2013-04-17 | — | — | EP | disclosed |
| US-20120071462-A1 | Dihydrobenzoxathiazepine compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2012-03-22 | — | — | US | disclosed |
| EP-2431360-A1 | Derivatives of dihydrobenzoxathiazepine, method of preparing same and pharmaceutical compositions containing them as well as their uses as modulators of AMPA receptors | Les Laboratoires Servier (FR) | 2012-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071462-A1 | Dihydrobenzoxathiazepine compounds, a process for their preparation and pharmaceutical compositions containing them | GABRA1, GRM1, GABRA5 | HDAC8 1383/4885CTNNB1 2961/4885WNT3A 4499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.